Metagenomi, Inc. (NASDAQ:MGX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Metagenomi, Inc. (NASDAQ:MGX) has received an average recommendation of “Moderate Buy” from the five brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $10.00.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Metagenomi in a research report on Monday, December 22nd.

Metagenomi Stock Performance

NASDAQ MGX opened at $1.52 on Monday. The company has a market cap of $57.08 million, a PE ratio of -0.63 and a beta of 0.45. The firm’s 50 day moving average price is $1.61 and its 200-day moving average price is $1.94. Metagenomi has a 52-week low of $1.23 and a 52-week high of $3.95.

Institutional Investors Weigh In On Metagenomi

A number of institutional investors have recently added to or reduced their stakes in MGX. Pura Vida Investments LLC grew its stake in Metagenomi by 260.1% in the second quarter. Pura Vida Investments LLC now owns 952,134 shares of the company’s stock valued at $1,409,000 after purchasing an additional 687,743 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Metagenomi by 276.3% in the 4th quarter. Renaissance Technologies LLC now owns 628,400 shares of the company’s stock valued at $1,018,000 after buying an additional 461,400 shares in the last quarter. Peapod Lane Capital LLC grew its position in shares of Metagenomi by 1.1% in the 3rd quarter. Peapod Lane Capital LLC now owns 513,815 shares of the company’s stock worth $1,218,000 after buying an additional 5,706 shares during the last quarter. Jane Street Group LLC raised its stake in shares of Metagenomi by 341.6% during the 4th quarter. Jane Street Group LLC now owns 433,859 shares of the company’s stock worth $703,000 after acquiring an additional 335,604 shares in the last quarter. Finally, Bridgeway Capital Management LLC raised its stake in shares of Metagenomi by 102.1% during the 4th quarter. Bridgeway Capital Management LLC now owns 395,800 shares of the company’s stock worth $641,000 after acquiring an additional 200,000 shares in the last quarter.

About Metagenomi

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.